Cystic Fibrosis trials in Canada

Showing 76 to 100 of 177. Each trial links to its page on Pharma Observatory.

• A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation NCT02823470·Phase 4·Terminated·Vertex Pharmaceuticals Incorporated·Started 2016
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation NCT02725567·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2016
• A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation NCT02742519·Phase 3·Terminated·Vertex Pharmaceuticals Incorporated·Started 2016
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del NCT02797132·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2016
• Measures of Respiratory Health (MRH) NCT02657837·Observational·Unknown status·The Hospital for Sick Children·Started 2016
• Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations NCT02606487·Observational·Completed·The Hospital for Sick Children·Started 2015
• Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC) NCT02518672·Phase 2·Terminated·SCF Pharma·Started 2015
• EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients NCT02443688·Phase 2·Completed·Celtaxsys, Inc.·Started 2015
• Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis NCT02456103·Phase 3·Terminated·PTC Therapeutics·Started 2015
• A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation NCT02516410·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor NCT02544451·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation NCT02565914·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease NCT02740868·Phase 2·Recruiting·The Hospital for Sick Children·Started 2015
• A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation NCT02514473·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis NCT02279498·Phase 3·Completed·Anthera Pharmaceuticals·Started 2015
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor NCT02412111·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients NCT02532764·Phase 1/2·Completed·ProQR Therapeutics·Started 2015
• Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients NCT02305784·Observational·Completed·Institut de Recherches Cliniques de Montreal·Started 2015
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation NCT02392234·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• Saline Hypertonic in Preschoolers + CT NCT02950883·Phase 2/3·Completed·University of Washington, the Collaborative Health Studies Coordinating Center·Started 2015
• Saline Hypertonic in Preschoolers NCT02378467·Not applicable·Completed·University of Washington, the Collaborative Health Studies Coordinating Center·Started 2015
• Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma NCT02334553·Phase 2·Completed·SolAeroMed Inc.·Started 2015
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor NCT02347657·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• HFN Versus NIV in Cystic Fibrosis. The HIFEN Study NCT02262871·Not applicable·Completed·Unity Health Toronto·Started 2014
• A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects NCT02134353·Phase 3·Completed·Syntara·Started 2014